Subsecond Analysis of Locomotor Activity in Parkinsonian Mice.

Journal: eNeuro
Published Date:

Abstract

The degeneration of midbrain dopamine (DA) neurons disrupts the neural control of natural behavior, such as walking, posture, and gait in Parkinson's disease. While some aspects of motor symptoms can be managed by DA replacement therapies, others respond poorly. Recent advancements in machine learning-based technologies offer opportunities to better understand the organizing principles of behavior modules at fine timescales and its dependence on dopaminergic modulation. In the present study, we applied the motion sequencing (MoSeq) platform to study the spontaneous locomotor activities of neurotoxin and genetic mouse models of parkinsonism as the midbrain DA neurons progressively degenerate. We also evaluated the treatment efficacy of levodopa (l-DOPA) on behavioral modules at fine timescales. We revealed robust changes in the kinematics and usage of the behavioral modules that encode spontaneous locomotor activity. Further analysis demonstrates that fast behavioral modules with higher velocities were more vulnerable to loss of DA and preferentially affected at early stages of Parkinsonism. Last, l-DOPA effectively improved the velocity, but not the usage and transition probability, of behavioral modules in parkinsonian animals. In conclusion, the hypokinetic phenotypes in parkinsonism involve the decreased velocities of behavioral modules and their disrupted temporal organization during movement. Moreover, we showed that the therapeutic effect of l-DOPA is mainly mediated by its effect on the velocities of behavior modules at fine timescales. This work documents robust changes in the velocity, usage, and temporal organization of behavioral modules and their responsiveness to dopaminergic treatment under the parkinsonian state.

Authors

  • Daniil Berezhnoi
    Department of Pharmacology and Physiology, Georgetown University of Medical Center, Washington DC, 20007, United States.
  • Hiba Douja Chehade
    Department of Pharmacology and Physiology, Georgetown University of Medical Center, Washington DC, 20007, United States.
  • Gabriel Simms
    Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI 49503, United States.
  • Liqiang Chen
    Department of Oncology, Liuzhou Workers' Hospital,The Fourth Affiliated Hospital of Guangxi Medical University, Liuazhou, China.
  • Kishore Kumar S Narasimhan
    Department of Psychiatry and Behavioral Sciences, Texas A&M Health Sciences Center, College of Medicine, Texas A&M University, College Station, TX 77845, United States.
  • Shashank M Dravid
    Department of Psychiatry and Behavioral Sciences, Texas A&M Health Sciences Center, College of Medicine, Texas A&M University, College Station, TX 77845, United States.
  • Hong-Yuan Chu
    Department of Pharmacology and Physiology, Georgetown University of Medical Center, Washington DC, 20007, United States hc948@georgetown.edu.